Skip to main content
Equibles

ADAR1 Capital Management, LLC

Position in URGN — UroGen Pharma Ltd.

CIK 1940272 AUSTIN, TX
Back to URGN Full portfolio

Position in URGN

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$9,288,136
+$2,177,784 QoQ
Shares Held
252,395
-36.2% QoQ
Ownership
0.516%
of shares outstanding
% of Portfolio
0.45%
of 13F equity value
Holder Rank
#30
of 190 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in URGN Over Time

Shares Held

Position Value (USD)

Derivatives in URGN

reported options exposure · as of Dec 31, 2025
CallValue
$936,800
CallShares
40,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ADAR1 Capital Management, LLC holds $1,760,528,411 across 192 Biotechnology names. URGN ranks #45 (0.5% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ABVX
Abivax S.A.
 1,804,703 $240,494,721
2 PTGX
Protagonist Therapeutics, Inc
 960,863 $117,782,586
3 ROIV
Roivant Sciences Ltd.
 3,157,008 $111,726,513
4 IMVT
Immunovant, Inc.
 2,330,716 $89,802,487
5 ZLAB
Zai Lab Ltd
 3,369,034 $64,011,646
6 AGIO
Agios Pharmaceuticals, Inc.
 1,288,053 $47,799,646
7 CRNX
Crinetics Pharmaceuticals, Inc.
 1,222,080 $45,730,233
8 CYTK
Cytokinetics Inc
 457,907 $39,009,097

All Filings in URGN

Export CSV
7 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $9,288,136 252,395
2026-03-31 $7,110,352 395,459
2025-12-31 $936,800 40,000
2025-12-31 $2,936,282 125,375
2025-09-30 $698,250 35,000
2025-09-30 $798,000 40,000
2025-06-30 $137,000 10,000